Navigation Links
WaferGen's MyDesign Open Platform Facilitates Rapid Development of a Proprietary Prostate Cancer Diagnostic Panel in the Lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center
Date:1/28/2013

FREMONT, Calif., Jan. 28, 2013 /PRNewswire/ -- WaferGen Bio-systems, Inc. (OTCBB: WGBS) today announced the results of a successful study of lncRNA markers associated with prostate cancer in the lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center.  The results can be viewed in white paper form at: 

http://www.wafergen.com/wp-content/uploads/2013/01/UM_lncRNA_TNf.pdf

Under an existing agreement, WaferGen holds a license to this and other lncRNA-based research reagents developed by Dr. Chinnaiyan's lab.

Dr. Arul Chinnaiyan , the S.P. Hicks Professor of Pathology and Urology at University of Michigan and the lead author of the study stated: "The WaferGen SmartChip system is an ideal technology to validate the expression of novel lncRNAs nominated by RNA-seq in a highly parallel fashion. It allows us to test multiple primer sets for qPCR very efficiently and cost-effectively, because of the platform's flexibility.  We were able to vary experiment formats in terms of number of analytes and samples that were driven by each experiment's design.  Furthermore, we could change content rapidly by dispensing assays in our own lab using WaferGen's multi-sample nano-dispenser.  We intend to validate a number of lncRNA panels for a variety of common solid tumors, and hope to translate the findings into clinical practice as proprietary diagnostics."     

The latest marker validation study further underscores the now dual-role of WaferGen's SmartChip system in enhancing and augmenting experiments using Next-Gen sequencing (NGS).  As recently announced, the system has shown promise upstream from NGS in target amplification, while downstream from NGS it can play a valuable role in target validation.  This capability will enable a lab to prepare samples for targeted resequencing, and to confirm the NGS results via high-throughput nano-qPCR.  Both applications leverage SmartChip's best-in-class flexibility, high levels of sensitivity and dynamic range without the need for pre-amplification, and a very low cost per reaction.

About WaferGen and the SmartChip Real-Time PCR System

WaferGen Bio-systems, Inc. is an innovative life science company that offers the SmartChip Real-Time PCR System—a next-generation genetic analysis platform for profiling and validating molecular biomarkers. It provides a range of high-throughput capabilities including microRNA and mRNA gene expression profiling as well as single nucleotide polymorphism (SNP) genotyping.   

For additional information, please see http://www.wafergen.com

Forward Looking Statements

This press release contains certain "forward-looking statements".  Such statements include statements relating to the expected benefits to the Company of using nano-qPCR technology for target enrichment sample preparation prior to targeted resequencing on Next-Gen platforms and other statements relating to future events that are not historical facts, including statements which may be preceded by the words "will," "believes" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the Company. Actual results may differ materially from the expectations contained in the forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2011. Security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. The Company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

WaferGen Contact:
John Harland
john.harland@wafergen.com
510-780-2395


'/>"/>
SOURCE WaferGen Bio-systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Fate Therapeutics Strengthens Its iPSC Platform
2. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
3. Medstreaming Launches Web-Based Analytics for All in One EMR/PACS/Practice Management Platform at HIMSS
4. WaferGen Bio-systems Announces Open Format qPCR Platform and Strategic Realignment
5. Luminex Corporation Receives CE Mark for Revolutionary Newborn Screening Platform
6. Cohera Medical Awarded Platform Patent on its Biodegradable Adhesive Technology
7. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
8. Baylor College of Medicine and Gradalis Enter Collaboration Agreement to Utilize Gradalis Bifunctional shRNA Platform in Translational Medicine Research
9. ESTEVE Communicates its R&D Through a New Interactive Platform
10. SomaGenics Reports Study on Mechanism of Action of Its Therapeutic Platform
11. Oncobiologics, Inc. Announces a Collaboration Agreement with XOMA Corporation to Utilize XOMAs Fully Human Antibody Libraries for Their Discovery Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... ... its patented GX-1 yeast production and fermentation process. The efficiencies created by ... on micro-organism technologies, most notably the ethanol industry wherein individual production plants are ...
(Date:6/26/2017)... ... June 26, 2017 , ... Third Wave Bioactives, LLC ... Sales Director, focused on leading new business development and ensuring quality customer experience. ... in the food ingredient industry in technical, marketing and sales roles. “Brett’s background working ...
(Date:6/23/2017)... ... June 23, 2017 , ... Biova, LLC., the leader in ... Biova’s Board of Directors. Dr. Henig will bring a wealth of scientific experience in ... as the Chief Technical and Scientific Officer of four major global companies in the ...
(Date:6/23/2017)... WI (PRWEB) , ... June ... ... announce the launch of a redesigned, easier-to-navigate website for all six of ... boards for physicians, nurses, dentists, pharmacists, physical and occupational therapists, and biotechnicians, ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
Breaking Biology News(10 mins):